Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis

ABSTRACT

Secukinumab represents the first IL-17A antagonist among the available biologic therapies approved for moderate-to-severe plaque psoriasis management. Secukinumab demonstrated greater efficacy over placebo, etanercept and ustekinumab in patients that had limited benefit from non-biologic systemic therapies and phototherapy. Despite standard-of-care systemic therapies being more likely to be cost-effective at this time, a Canadian cost-utility analysis found secukinumab to display benefit in quality-of-life gains in moderate-to-severe plaque psoriasis patients, and greater cost-effectiveness when compared to other biologic systemic therapies. Determination of the true economic value of secukinumab amongst the available therapies for moderate-to-severe plaque psoriasis will require continued economic evaluation.

KEYWORDS:

• secukinumab
• biologics
• cost-effectiveness
• economics
• plaque psoriasis

Financial & competing interests disclosure

K Shojania is a member of the advisory board, and Speaker’s Bureau for Amgen, Pfizer Inc., Janssen-Ortho Biotech, UCB, Roche and Celgene. J Dutz is a member of the advisory board and Speaker’s Bureau for Janssen-Ortho Biotech, Abbvie, Amgen, Leo Pharma, Novartis and Biogen Idec. He has also been an investigator on clinical trials by Centocor, ONO Pharmaceuticals and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.